Preview

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 9, No 2 (2016) BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION Abstract  similar documents
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak
"... -year cumulative increase in drug costs (RUB 1,008 million) will be offset by a decrease in non-drug ..."
 
Vol 8, No 1 (2015) BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina
"... in the first line of therapy of a multiple myeloma for patients more senior 65 years old with clinical ..."
 
Vol 7, No 2 (2014) PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Abstract  similar documents
A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin
"... years old with clinical manifestations of a polineuropathy, which autological transplantation of stem ..."
 
Vol 6, No 4 (2013) Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа Abstract  similar documents
A. Yu. Kulikov, I. V. Novikov
"... improvement from the perspective of quality adjusted life-years. Simultaneously liraglutide demonstrates ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... the cost rate to 289 199 RUB in 10 years. ..."
 
Vol 8, No 1 (2015) PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION Abstract  similar documents
M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach
"... spending starting from the first year; the total five-year budget savings are 275 RUB millions.  ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... эффективности, в качестве критериев эффективности были использованы значения добавленных лет жизни (LYG) и ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... at the same time constitute 5 213 900 000 rub. (670.5 to 1184.3 million rubles per year). Calculated unit ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment Abstract  similar documents
A. U. Kulikov, V. V. Babiy
"... year. Diabetes treatment schemes mostly focused on normalizing the blood glucose level. To achieve ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... , myorelaxants, physical therapy). Measured direct costs at 1-year follow-up. Quality of life was measured ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... of BV in patients with relapsed or refractory CD30-positive HL. Time horizon of the model was 40 years ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... year respectively, administration of Lacosamide as concomitant drug, in comparison with standard ..."
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... and gender groups, as well as the volume of government spending. The cost of disability-adjusted life-year ..."
 
Vol 11, No 4 (2018) International experience in determining the cost-effectiveness thresholds Abstract  similar documents
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky
"... , which is represented by quality-adjusted life year (QALY) in most counties. However,PolandandBrazilallow ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... that dapagliflozin introduction could delay the start of insulin treatment by an average of 6.5 years that in turn ..."
 
Vol 9, No 1 (2016) SYSTEMATIC REVIEW OF PENTAGLOBIN EFFICACY IN PREVENTING MORTALITY IN NEWBORNS AND OLDER CHILDREN WITH BACTERIAL INFECTIONS AND SEPSIS Abstract  similar documents
V. K. Fedyaeva, O. Yu. Rebrova
"... от любых причин при бактериальных инфекциях и сепсисе у детей до двух лет Федяева В.К.1, Реброва ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... will be 69,305 million RUB/year, taking into account the accepted assumptions. Under the assumption of equal ..."
 
Vol 9, No 3 (2016) HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE Abstract  similar documents
A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
"...  criteria of RA treatment were: patient-years in remission and patient-years in low disease activity. We ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT Abstract  similar documents
N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova
"... , травматические, постинфекционные, опухолевые и др.) [9,19]. При СЛГ случаются судорожные приступы тонического ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... % and 7% for the first, second and third year is expected to result in cost savings of 26.4 million rubles ..."
 
Vol 8, No 2 (2015) CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA Abstract  similar documents
Elena Albertovna Sobko, Natalya Vladimirovna Gordeeva, Angelina Yurievna Kraposhina, Irina Anatolyevna Soloveva, Svetlana Vladimirovna Chubarova, Olga Petrovna Ishenko, Irina Vladimirovna Demko, Maria Michailovna Loktionova
"... улучшение следующих показателей: ОФВ1, уменьшение дневных и ночных приступов удушья, количества обострений ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... with the same efficacy. Budgetary spending is decreased by 1.68 bln. rubles over 5 years with a gradual increase ..."
 
Vol 7, No 3 (2014) ECONOMIC JUSTIFICATION FOR TELEHEALTH TECHNOLOGY USE FOR PREVENTIVE MEDICAL EXAMINATION OF THE POPULATION IN REMOTE REGIONS Abstract  similar documents
D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky
"... than one and a half years to coverage increase by medical care of the handicapped and removed ..."
 
Vol 7, No 4 (2014) IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? Abstract  similar documents
V. V. Omelyanovskiy
"... in Russia for several years already, while national or internal reference pricing system hasn’t been applied ..."
 
Vol 8, No 1 (2015) SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION Abstract  similar documents
A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova
"... caused with the studied diseases and the number of lost Disability Adjusted Life Years (DALY ..."
 
1 - 25 of 136 Items 1 2 3 4 5 6 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)